Dynavax(DVAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

DVAX Dynavax

Market Closed 05-31 16:00:00 EDT

11.99

+0.17

+1.44%

盘后11.99

+0.000.00%

18:05 EDT

High12.06	Low11.79	Vol2.93M
Open11.83	D1 Closing11.82	Amplitude2.28%
Mkt Cap1.57B	Tradable Cap1.45B	Total Shares130.89M
T/O35.11M	T/O Rate2.42%	Tradable Shares121.27M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"DVAX","market":"US","secType":"STK","nameCN":"Dynavax","latestPrice":11.99,"timestamp":1717185600000,"preClose":11.82,"halted":0,"volume":2934354,"hourTrading":{"tag":"盘后","latestPrice":11.99,"preClose":11.99,"latestTime":"18:05 EDT","volume":1040562,"amount":12476336.0799,"timestamp":1717193114230},"delay":0,"floatShares":121272844,"shares":130891710,"eps":0.067704,"marketStatus":"Market Closed","change":0.17,"latestTime":"05-31 16:00:00 EDT","open":11.83,"high":12.06,"low":11.79,"amount":35111517.495888,"amplitude":0.022843,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.067704,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1717401600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1077166800000,"exchange":"NASDAQ","adjPreClose":11.82,"postHourTrading":{"tag":"盘后","latestPrice":11.99,"preClose":11.99,"latestTime":"18:05 EDT","volume":1040562,"amount":12476336.0799,"timestamp":1717193114230},"volumeRatio":1.2067835868754828,"impliedVol":0.2341,"impliedVolPercentile":0.0397},"requestUrl":"/m/hq/s/DVAX","defaultTab":"news","newsList":[{"id":"2439538483","title":"Dynavax to Present at Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2439538483","media":"PR Newswire","top":-1,"share":"https://ttm.financial/m/news/2439538483?lang=en_us&edition=fundamental","pubTime":"2024-05-29 04:15","pubTimestamp":1716927300,"startTime":"0","endTime":"0","summary":"EMERYVILLE, Calif., May 28, 2024 /PRNewswire/ --Dynavax Technologies Corporation , a commercial-stage biopharmaceutical company developing andcommercializing innovative vaccines, today announced that the Company will present at the following upcoming investor conferences during the month of June:. William Blair 44th Annual Growth Stock Conference on Tuesday, June 4 at 1:20 p.m. CT. Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10 at 4:00 p.m. ET. Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B vaccine [Hepatitis B Vaccine , Adjuvanted], which is approved in the U.S., the European Union and Great Britain for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018 adjuvant, currently used in multiple adjuvanted COVID-19 vaccines.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/NJmFzlNyouvBOFrctfvzVQ--~B/aD01Nzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/2388756ff209700ef70b897d8f57192b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/NJmFzlNyouvBOFrctfvzVQ--~B/aD01Nzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/2388756ff209700ef70b897d8f57192b"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/dynavax-present-upcoming-investor-conferences-201500608.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dynavax-present-upcoming-investor-conferences-201500608.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2435549091","title":"Analysts Conflicted on These Healthcare Names: 4D Molecular Therapeutics (FDMT), Dynavax (DVAX) and Natera (NTRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2435549091","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2435549091?lang=en_us&edition=fundamental","pubTime":"2024-05-15 01:30","pubTimestamp":1715707815,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on 4D Molecular Therapeutics (FDMT – Research Report), Dynavax (DVAX...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-4d-molecular-therapeutics-fdmt-dynavax-dvax-and-natera-ntra?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-4d-molecular-therapeutics-fdmt-dynavax-dvax-and-natera-ntra?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2435514743","title":"Hold Rating on Dynavax Amidst FDA Setback and Long-term Profitability Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2435514743","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2435514743?lang=en_us&edition=fundamental","pubTime":"2024-05-14 22:25","pubTimestamp":1715696724,"startTime":"0","endTime":"0","summary":"In a report released today, Paul Choi from Goldman Sachs maintained a Hold rating on Dynavax (DVAX – Research Report), with a price target of $20.0...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/hold-rating-on-dynavax-amidst-fda-setback-and-long-term-profitability-focus?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/hold-rating-on-dynavax-amidst-fda-setback-and-long-term-profitability-focus?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2435514704","title":"Analysts’ Top Healthcare Picks: aTyr Pharma (LIFE), Dynavax (DVAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2435514704","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2435514704?lang=en_us&edition=fundamental","pubTime":"2024-05-14 22:20","pubTimestamp":1715696408,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on aTyr Pharma (LIFE – Research Report) and Dynavax (DV...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-atyr-pharma-life-dynavax-dvax?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-atyr-pharma-life-dynavax-dvax?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2435303513","title":"BUZZ-Dynavax falls as FDA declines expanded use of hepatitis B vaccine in dialysis patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2435303513","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2435303513?lang=en_us&edition=fundamental","pubTime":"2024-05-14 20:57","pubTimestamp":1715691479,"startTime":"0","endTime":"0","summary":"** Shares of vaccine maker Dynavax Technologies    fall 6.6% to $10.30 premarket.   ** Co says FDA has declined to approve the expanded use of its hepatitis B vaccine in adults on hemodialysis   ** The health regulator said the application did not provide sufficient data to support the full evaluation of effectiveness or safety of a four-dose regimen of the vaccine, known as Heplisav-B   ** The decision has no impact on the approved indication for the vaccine in the U.S. for known subtypes of hepatitis B virus in adults - DVAX   ** Adds it also doesn't affect the approval decision received from the European Commission in October 2023 for the four-dose regimen for the adult hemodialysis population   ** Up to last close, stock down 21% YTD ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2435951827","title":"Dynavax Application for Hepatitis B Treatment Ruled Insufficient by FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2435951827","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2435951827?lang=en_us&edition=fundamental","pubTime":"2024-05-14 20:52","pubTimestamp":1715691120,"startTime":"0","endTime":"0","summary":"Dynavax disclosed that the Food and Drug Administration has ruled its application for its hepatitis B vaccine treatment didn't provide sufficient data to support the full evaluation of its effectiveness or safety.The commercial-stage biopharmaceutical company said the decision came in a letter from the FDA in response to its supplement biologics license application. The ruling pertained to the four-dose Heplisav-B vaccine regimen for adults on hemodialysis.\"We are reviewing the agency's feedback and intend to request a meeting with the FDA to evaluate options for providing additional data to support the four-dose regimen,\" said Chief Medical Officer Rob Janssen.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2435185785","title":"US FDA declines to approve expanded use of Dynavax's hepatitis B vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2435185785","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2435185785?lang=en_us&edition=fundamental","pubTime":"2024-05-14 20:36","pubTimestamp":1715690195,"startTime":"0","endTime":"0","summary":"May 14  - The U.S. Food and Drug Administration has declined to approve the expanded use of Dynavax Technologies'    hepatitis B vaccine in patients undergoing hemodialysis, the company said on Tuesday. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2435659078","title":"Dynavax Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B® Regimen for Adults on Hemodialysis in the U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2435659078","media":"PR Newswire","top":-1,"share":"https://ttm.financial/m/news/2435659078?lang=en_us&edition=fundamental","pubTime":"2024-05-14 20:30","pubTimestamp":1715689800,"startTime":"0","endTime":"0","summary":"EMERYVILLE, Calif., May 14, 2024 /PRNewswire/ --Dynavax Technologies Corporation todayprovided a regulatory update for the Company's supplemental Biologics License Application  to include a four-dose HEPLISAV-B vaccine [Hepatitis B Vaccine , Adjuvanted] regimen for adults on hemodialysis. The U.S. Food and Drug Administration  has issued a Complete Response Letter  in response to the sBLA, stating that the application did not provide sufficient data to support the full evaluation of effectiveness or safety of a four-dose regimen of HEPLISAV-B. The CRL has no impact on the approved indication for HEPLISAV-B in the U.S., the European Union, and Great Britain, which is for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The CRL also does not affect the approval decision received from the European Commission in October 2023 for the four-dose HEPLISAV-Bregimen for the adult hemodialysis population.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/NJmFzlNyouvBOFrctfvzVQ--~B/aD01Nzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/2388756ff209700ef70b897d8f57192b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/NJmFzlNyouvBOFrctfvzVQ--~B/aD01Nzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/2388756ff209700ef70b897d8f57192b"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/dynavax-provides-regulatory-sbla-four-123000510.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dynavax-provides-regulatory-sbla-four-123000510.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434854867","title":"Dynavax Technologies Corp (DVAX) Q1 2024 Earnings: Aligns with EPS Projections, Surpasses ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2434854867","media":"GuruFocus.com","top":-1,"share":"https://ttm.financial/m/news/2434854867?lang=en_us&edition=fundamental","pubTime":"2024-05-11 01:43","pubTimestamp":1715362987,"startTime":"0","endTime":"0","summary":"Total Revenue: Reported at $50.8 million for Q1 2024, an increase from $46.9 million in Q1 2023, but fell short of the estimated revenue of $54.98 million.Net Product Revenue: HEPLISAV-B vaccine net product revenue rose to $47.8 million, up 10% year-over-year, contributing significantly to the total revenue.GAAP Net Loss: Recorded at $8.7 million for Q1 2024, a notable improvement from a net loss of $24.3 million in Q1 2023, but fell short of the estimated net loss of $4.26 million.Earnings Per Share : GAAP EPS stood at -$0.07, showing an improvement from -$0.19 in the previous year, but below the estimated EPS of -$0.02.Market Share Growth: HEPLISAV-B's market share in the U.S. retail pharmacy segment increased to approximately 55%, up from 49% in Q1 2023.Dynavax Technologies Corp , a prominent biopharmaceutical company, disclosed its financial outcomes for the first quarter of 2024 on May 8, 2024, through its 8-K filing. The company focuses on developing and commercializing innovativ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dynavax-technologies-corp-dvax-q1-174307933.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434859053","title":"Dynavax: HEPLISAV-B Growth Up, Pipeline Uncertain","url":"https://stock-news.laohu8.com/highlight/detail?id=2434859053","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2434859053?lang=en_us&edition=fundamental","pubTime":"2024-05-10 21:02","pubTimestamp":1715346133,"startTime":"0","endTime":"0","summary":"HEPLISAV-B Q1 revenue was $48 million, showing 10% YoY growth.Dynavax's shingles and Tdap vaccines advanced in clinical stages, with data anticipated in the coming quarters.Dynavax's balance sheet rem","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1316007813/image_1316007813.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1316007813/image_1316007813.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4691803-dynavax-heplisav-b-growth-up-pipeline-uncertain","is_publish_highlight":false,"gpt_icon":0},{"id":"2434067191","title":"Analysts Offer Insights on Healthcare Companies: LifeMD (LFMD), NeuroPace (NPCE) and Dynavax (DVAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2434067191","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2434067191?lang=en_us&edition=fundamental","pubTime":"2024-05-09 18:30","pubTimestamp":1715250651,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on LifeMD (LFMD – Research Report), NeuroPace (NPCE – R...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-lifemd-lfmd-neuropace-npce-and-dynavax-dvax?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-lifemd-lfmd-neuropace-npce-and-dynavax-dvax?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2434057414","title":"Dynavax Technologies Corp (DVAX) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2434057414","media":"GuruFocus.com","top":-1,"share":"https://ttm.financial/m/news/2434057414?lang=en_us&edition=fundamental","pubTime":"2024-05-09 15:40","pubTimestamp":1715240434,"startTime":"0","endTime":"0","summary":"HEPLISAV-B Net Product Revenue: Grew 10% year-over-year to $48 million in Q1 2024.Cost of Product Sales: Decreased to $11 million in Q1 2024 from $15 million in Q1 2023.Gross Margin: Improved to approximately 77% in Q1 2024 from 66% in Q1 2023.Other Revenue: Remained stable at $3 million in Q1 2024, primarily from the plague vaccine program funded by the US Department of Defense.Research and Development Expenses: Consistent at $14 million for Q1 2024 and Q1 2023.Selling, General and Administrative Expenses: Increased to $44 million in Q1 2024 from $37 million in Q1 2023.Net Loss: Reduced to $9 million in Q1 2024 from $24 million in Q1 2023.Cash Position: Ended Q1 2024 with $724 million in cash, cash equivalents, and marketable securities.GuruFocus has detected 5 Warning Signs with DVAX.Dynavax Technologies Corp  maintains a strong financial position with $724 million in cash, cash equivalents, and marketable securities, sufficient to support its current pipeline assets and organic busi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dynavax-technologies-corp-dvax-q1-074034004.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434205548","title":"Dynavax Technologies (DVAX) Q1 2024 Earnings Call Transcript","url":"https://stock-news.laohu8.com/highlight/detail?id=2434205548","media":"Motley Fool Transcribing","top":-1,"share":"https://ttm.financial/m/news/2434205548?lang=en_us&edition=fundamental","pubTime":"2024-05-09 14:15","pubTimestamp":1715235316,"startTime":"0","endTime":"0","summary":"DVAX earnings call for the period ending March 31, 2024.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com/earnings/call-transcripts/2024/05/09/dynavax-technologies-dvax-q1-2024-earnings-call-tr/","is_publish_highlight":false,"gpt_icon":0},{"id":"2434307036","title":"Dynavax drops 6% as quarterly results miss on both lines","url":"https://stock-news.laohu8.com/highlight/detail?id=2434307036","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2434307036?lang=en_us&edition=fundamental","pubTime":"2024-05-09 05:45","pubTimestamp":1715204739,"startTime":"0","endTime":"0","summary":"Dynavax  is down ~6% in after-hours trading Wednesday after posting Q1 2024 results that missed on both lines. The company also reaffirmed its earlier 2024 guidance. It sees product revenue of its hepatitis b vaccine HEPLISAV-B -- its only marketed product -- of $265M-$280M. Consensus for overall revenue is $287.96M.  In the quarter, Dynavax  saw its net loss narrow ~64 % year over year to ~$8.7M. Net loss per share, basic and diluted, went to -$0.07 from -$0.19. At the end of the quarter , the company reported cash, cash equivalents, and marketable securities of $723.5M compared to $742.3M on Dec. 31, 2023. However, Dynavax said it expects to have more of this figure on Dec. 31, 2024 than at the end of 2023.","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186975279/image_186975279.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186975279/image_186975279.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4103264-dynavax-drops-6-quarterly-results-miss-both-lines","is_publish_highlight":false,"gpt_icon":0},{"id":"2434508322","title":"Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2434508322","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2434508322?lang=en_us&edition=fundamental","pubTime":"2024-05-09 05:20","pubTimestamp":1715203207,"startTime":"0","endTime":"0","summary":"Dynavax Technologies  came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.19 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -40%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.01 per share when it actually produced break-even earnings, delivering a surprise of 100%.Dynavax Technologies , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $50.79 million for the quarter ended March 2024, missing the Zacks Consensus Estimate by 2.29%. This compares to year-ago revenues of $46.93 million. The company has topped consensus revenue estimates two times over the last four quarters.Dynavax Technologies shares have lost about 15.9% since the beginning of the year versus the S&P 500's gain of 8.8%.While Dynavax Technologies has underperformed the market","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/132juehTNIyEUn7pK7.GPA--~B/aD01MDY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3d7c5b2146ac04ffd51752e17ff2a619","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/132juehTNIyEUn7pK7.GPA--~B/aD01MDY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3d7c5b2146ac04ffd51752e17ff2a619"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dynavax-technologies-dvax-reports-q1-212007836.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434703859","title":"Dynavax Technologies Q1 2024 GAAP EPS $(0.07) Misses $(0.03) Estimate, Sales $50.790M Miss $54.975M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2434703859","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2434703859?lang=en_us&edition=fundamental","pubTime":"2024-05-09 04:02","pubTimestamp":1715198549,"startTime":"0","endTime":"0","summary":"Dynavax Technologies (NASDAQ:DVAX) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.03) by 133.33 percent.  The company reported quarterly sales of $50.790 million which","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/05/38712044/dynavax-technologies-q1-2024-gaap-eps-0-07-misses-0-03-estimate-sales-50-790m-miss-54-975m-estimate","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.dynavax.com","stockEarnings":[{"period":"1week","weight":0.0527},{"period":"1month","weight":0.0265},{"period":"3month","weight":-0.0603},{"period":"6month","weight":-0.1305},{"period":"1year","weight":0.0444},{"period":"ytd","weight":-0.1423}],"compareEarnings":[{"period":"1week","weight":-0.0039},{"period":"1month","weight":0.054},{"period":"3month","weight":0.0283},{"period":"6month","weight":0.1487},{"period":"1year","weight":0.2502},{"period":"ytd","weight":0.1095}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.001226},{"month":2,"riseRate":0.4,"avgChangeRate":-0.032132},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.004913},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.001867},{"month":5,"riseRate":0.52381,"avgChangeRate":0.03134},{"month":6,"riseRate":0.5,"avgChangeRate":0.028314},{"month":7,"riseRate":0.55,"avgChangeRate":0.058311},{"month":8,"riseRate":0.45,"avgChangeRate":0.048636},{"month":9,"riseRate":0.45,"avgChangeRate":-0.029186},{"month":10,"riseRate":0.45,"avgChangeRate":-0.008348},{"month":11,"riseRate":0.55,"avgChangeRate":0.039012},{"month":12,"riseRate":0.55,"avgChangeRate":0.141881}],"exchange":"NASDAQ","name":"Dynavax","nameEN":"Dynavax"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.5","shortVersion":"4.22.5","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Dynavax(DVAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Dynavax(DVAX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Dynavax,DVAX,Dynavax股票,Dynavax股票老虎,Dynavax股票老虎国际,Dynavax行情,Dynavax股票行情,Dynavax股价,Dynavax股市,Dynavax股票价格,Dynavax股票交易,Dynavax股票购买,Dynavax股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Dynavax(DVAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Dynavax(DVAX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction